PILL - Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
19.58
-0.04 (-0.22%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close19.62
Open19.70
Bid18.92 x 800
Ask19.99 x 1000
Day's Range19.16 - 20.40
52 Week Range11.23 - 29.45
Volume33,459
Avg. Volume34,444
Net Assets10.06M
NAV19.49
PE Ratio (TTM)N/A
Yield1.06%
YTD Daily Total Return-9.09%
Beta (5Y Monthly)0.00
Expense Ratio (net)0.99%
Inception Date2017-11-15
  • Best Leveraged ETF Areas of Last Week
    Zacks

    Best Leveraged ETF Areas of Last Week

    These leveraged ETFs posted solid gains last week.

  • 5 Leveraged ETFs That Gained More Than 20% in October
    Zacks

    5 Leveraged ETFs That Gained More Than 20% in October

    We have highlighted five leveraged equity ETFs that piled up more than 20% returns in October and could continue to be investors' darlings.

  • What Kind Of Shareholder Appears On The Canntab Therapeutics Limited's (CNSX:PILL) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Canntab Therapeutics Limited's (CNSX:PILL) Shareholder Register?

    If you want to know who really controls Canntab Therapeutics Limited (CNSX:PILL), then you'll have to look at the...

  • ETF Trends

    4 Hot Pharmaceutical ETFs

    Pharmaceutical ETFs invest in stocks of companies that are involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. With Johnson and Johnson continuing ...

  • ETF Trends

    Direxion to Change Indexes For Leveraged Pharma, Real Estate ETFs

    Direxion, one of the largest issuers of leveraged exchange traded funds, is planning to change the indexes its leveraged pharmaceuticals and real estate ETFs track. Currently, the Direxion Daily Pharmaceutical ...

  • PR Newswire

    Direxion Changes Investment Objective and Index of Three Leveraged ETFs

    NEW YORK , May 31, 2019 /PRNewswire/ -- The Board of Trustees of the Direxion Shares ETF Trust ("Trust") has approved changes to the investment objective, investment strategy and underlying index ...

  • Volatility 101: Should Canntab Therapeutics (CNSX:PILL) Shares Have Dropped 11%?
    Simply Wall St.

    Volatility 101: Should Canntab Therapeutics (CNSX:PILL) Shares Have Dropped 11%?

    The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

  • ETF Trends

    4 ETFs to Consider with Big Pharma on the Senate’s Hot Seat

    Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.

  • ETF Trends

    ‘PILL’ ETF Gains on $21.4B GE Biopharma Business Sale

    The Daily Pharmaceutical & Medical Bull 3X Shares (PILL)  gained 1.35 percent on news that General Electric will sell its biopharmaceutical business to conglomerate company Danaher for $21.4 billion. The sale comes as GE CEO Larry Culp is looking to take the company out of its worst slump in its 127-year history.

  • ETF Trends

    Big Biopharma Mergers Could Fuel These ETFs in 2019

    According to a report by the Silicon Valley Bank, biopharma deals in 2018 totaled $49 billion and more mergers in 2019 could continue providing growth in the industry, fueling ETFs like  Daily Pharmaceutical & Medical Bull 3X Shares  (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) . This was evident early in the new year as the biopharma space began 2019 with Bristol-Myers Squibb offering $74 billion to take over Celgene--a deal that could allow Bristol to become a top five pharmaceutical giant. RBC Capital Markets analyst Brian Abrahams said there's "a strong need to diversify around maturing franchises with (patents expiring) and biotech valuations having come down.